search

Active clinical trials for "Thyroid Diseases"

Results 1-10 of 930

Efficacy and Safety of Tocilizumab for TAO

TocilizumabThyroid Associated Ophthalmopathy

This study aims to evaluate the efficacy and safety of tocilizumab treating Thyroid Associated Ophthalmopathy.

Recruiting13 enrollment criteria

A Randomized, Double-masked, Placebo-controlled Safety, Tolerability, and Efficacy Study of VRDN-001,...

Thyroid Eye Disease

A randomized, double-masked, placebo-controlled safety, tolerability and efficacy study of VRDN-001 in participants with chronic thyroid eye disease (TED)

Recruiting14 enrollment criteria

Efficacy and Safety of Lonigutamab in Subjects With Thyroid Eye Disease (TED)

Thyroid Eye Disease

Phase 1/2, multicenter, multiple dose clinical study designed to evaluate lonigutamab in subjects with TED.

Recruiting18 enrollment criteria

Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC

Thyroid CancerThyroid Carcinoma4 more

This research is being done to determine the efficacy of selpercatinib to restore radioactive iodine (I-131) uptake and allow for I-131 treatment in people with RET fusion-positive radioiodine-refractory thyroid cancer. This research study involves the study drug selpercatinib in combination with standard of care treatments, I-131 and thyrotropin alfa (rhTSH).

Recruiting52 enrollment criteria

Safety of Endoscopic Thyroidectomy Via Retro-Auricular Single-Site Approach, Transoral Approach...

Papillary Thyroid Carcinoma

The goal of this retrospective study is to compare the safety and efficiacy of endoscopic thyroidectomy via retro-auricular single-site approach, transoral endoscopic thyroidectomy vestibular approach and transareola approach.

Recruiting10 enrollment criteria

Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease

Thyroid Eye Disease

To evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.

Recruiting19 enrollment criteria

Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma

Medullary Thyroid Cancer

This is a real world study aiming to observe the efficacy and safety of Anlotinib capsules in patients with advanced medullary thyroid carcinoma, and to summarize the treatment experience in a broad population of patients.

Recruiting23 enrollment criteria

A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive...

Non-Small Cell Lung CancerMedullary Thyroid Cancer2 more

This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.

Recruiting39 enrollment criteria

Active Surveillance Versus Surgery in Thyroid Papillary Microcarcinoma

Papillary Microcarcinoma of the Thyroid

The primary objective of this study is to evaluate the outcome of two treatment approaches (immediate surgery or close follow-up) in patients with papillary thyroid microcarcinoma (mPTc) .

Recruiting10 enrollment criteria

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS...

Malignant Solid NeoplasmRecurrent Adrenal Gland Pheochromocytoma39 more

This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have recurred or spread to other places in the body (advanced), lymphoma, or histiocytic disorders, that have a genetic alteration in the gene HRAS. Tipifarnib may block the growth of cancer cells that have specific genetic changes in a gene called HRAS and may reduce tumor size.

Recruiting60 enrollment criteria
12...93

Need Help? Contact our team!


We'll reach out to this number within 24 hrs